Dimension Therapeutics, Inc. (DMTX): K. Reed Clark , SVP of Pharmaceutical Develop of Dimension Therapeutics, Inc. sold 5,000 shares on Jun 7, 2016. The Insider selling transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were sold at $10.00 per share for a total value of $50,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Oct 29, 2015, Rishi Gupta (director 10% owner) purchased 200,000 shares at $13.00 per share price.On Oct 29, 2015, Michael Dybbs (director) purchased 961,538 shares at $13.00 per share price.
Company has been under the radar of several Street Analysts.Dimension Therapeutics Inc is Initiated by Cantor Fitzgerald to Buy and the brokerage firm has set the Price Target at $32. The Rating was issued on Jun 3, 2016.Dimension Therapeutics Inc is Initiated by Jefferies to Buy. The Rating was issued on Jun 2, 2016.Dimension Therapeutics Inc is Downgraded by Goldman to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Mar 30, 2016.
Dimension Therapeutics Inc. is a United States-based gene therapy company focused on developing novel treatments for rare diseases. The Company is focused on developing treatments for hemophilia A hemophilia B and rare genetic diseases. The Company’s adeno-associated virus (AAV) vector technology enables for systemic administration of the gene therapy in vivo for the treatment of an array of single-gene rare diseases. The Company is conducting pre-clinical development activities for its program in hemophilia A. The Company also has access to NAV vector technology in a range of rare disease indications.